GlassScriptPhysician profile
Stephanie Helminiak
NPI 1043785959
$11,099.75
in general payments reported to CMS, 2019-2025
34 companies · $5,108 in 2025
The $5,108 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,613 · 2024: $4,379 · 2025: $5,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,282.32 |
| Education | $817.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,818.46 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,627.80 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $1,192.98 | 2023-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $913.84 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $767.03 | 2023-2025 | Otezla, Otezla, Enbrel |
| Ucb, INC. | $659.46 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $636.11 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $494.11 | 2023-2025 | |
| Lilly USA, LLC | $419.45 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $279.74 | 2023-2025 | |
| Incyte Corporation | $255.73 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $251.29 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Galderma Laboratories, L.P. | $249.69 | 2024-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $246.27 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $171.67 | 2023-2025 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $168.15 | 2024-2025 | Zoryve |
| Organon LLC | $152.71 | 2023-2025 | Hadlima |
| Cipher Pharmaceuticals US LLC | $106.05 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $101.25 | 2023-2025 | Ycanth |
| Genentech USA, INC. | $83.81 | 2023-2024 | Erivedge, Xolair |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.82 | 2024-2025 | Spevigo, Cyltezo |
| Botanix Sb INC | $57.94 | 2025 | Sofdra |
| Convatec INC. | $49.68 | 2024-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $41.48 | 2025 | Valchlor |
| Mallinckrodt Hospital Products INC. | $41.20 | 2025 | Acthar |
| Tactile Systems Technology INC | $33.73 | 2024 | Flexitouch Plus, Entre Plus |
| Lnhc, INC | $24.47 | 2025 | Zelsuvmi |
| Kerecis Limited | $23.74 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Fresenius Kabi USA, LLC | $23.06 | 2023 | Idacio |
| Organogenesis INC. | $21.24 | 2025 | Affinity |
| Journey Medical Corporation | $16.25 | 2025 | |
| Mayne Pharma Commercial LLC | $15.37 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Helminiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.